BCL6 is altered in 9.27% of diffuse large B-cell lymphoma patients [3].

BCL6 is an inclusion criterion in 64 clinical trials for diffuse large B-cell lymphoma, of which 54 are open and 10 are closed. Of the trials that contain BCL6 status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 18 are phase 1 (13 open), 12 are phase 1/phase 2 (11 open), 22 are phase 2 (19 open), 3 are phase 2/phase 3 (2 open), 7 are phase 3 (7 open), and 1 is no phase specified (1 open) [4].

BCL6 is an inclusion criterion in 37 clinical trials for double-hit lymphoma, of which 31 are open and 6 are closed. Of the trials that contain BCL6 status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 11 are phase 1 (9 open), 5 are phase 1/phase 2 (4 open), 14 are phase 2 (12 open), 3 are phase 2/phase 3 (2 open), and 3 are phase 3 (3 open) [4].

BCL6 is altered in 8.72% of diffuse large B-cell lymphoma, not otherwise specified patients [3].

BCL6 is an inclusion criterion in 33 clinical trials for diffuse large B-cell lymphoma, not otherwise specified, of which 32 are open and 1 is closed. Of the trials that contain BCL6 status and diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 8 are phase 1 (8 open), 6 are phase 1/phase 2 (5 open), 11 are phase 2 (11 open), 1 is phase 2/phase 3 (1 open), 6 are phase 3 (6 open), and 1 is no phase specified (1 open) [4].

BCL6 is an inclusion criterion in 30 clinical trials for triple-hit lymphoma, of which 26 are open and 4 are closed. Of the trials that contain BCL6 status and triple-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 10 are phase 1 (9 open), 4 are phase 1/phase 2 (3 open), 10 are phase 2 (9 open), 3 are phase 2/phase 3 (2 open), and 2 are phase 3 (2 open) [4].

BCL6 is an inclusion criterion in 28 clinical trials for transformed non-hodgkin lymphoma, of which 26 are open and 2 are closed. Of the trials that contain BCL6 status and transformed non-hodgkin lymphoma as inclusion criteria, 6 are phase 1 (5 open), 9 are phase 1/phase 2 (8 open), 9 are phase 2 (9 open), 1 is phase 2/phase 3 (1 open), and 3 are phase 3 (3 open) [4].

BCL6 is altered in 55.56% of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements patients [3].

BCL6 is an inclusion criterion in 24 clinical trials for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 24 are open and 0 are closed. Of the trials that contain BCL6 status and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 5 are phase 1 (5 open), 6 are phase 1/phase 2 (6 open), 7 are phase 2 (7 open), 1 is phase 2/phase 3 (1 open), 4 are phase 3 (4 open), and 1 is no phase specified (1 open) [4].

BCL6 is an inclusion criterion in 22 clinical trials for high grade B-cell lymphoma, not otherwise specified, of which 21 are open and 1 is closed. Of the trials that contain BCL6 status and high grade B-cell lymphoma, not otherwise specified as inclusion criteria, 7 are phase 1 (7 open), 1 is phase 1/phase 2 (1 open), 9 are phase 2 (9 open), 2 are phase 2/phase 3 (1 open), 2 are phase 3 (2 open), and 1 is no phase specified (1 open) [4].

BCL6 is an inclusion criterion in 17 clinical trials for T-cell/histiocyte-rich large B-cell lymphoma, of which 17 are open and 0 are closed. Of the trials that contain BCL6 status and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 4 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), 5 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 4 are phase 3 (4 open) [4].

BCL6 is an inclusion criterion in 14 clinical trials for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 13 are open and 1 is closed. Of the trials that contain BCL6 status and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 2 are phase 1 (2 open), 5 are phase 1/phase 2 (4 open), 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [4].

BCL6 is an inclusion criterion in 14 clinical trials for grade 3b follicular lymphoma, of which 14 are open and 0 are closed. Of the trials that contain BCL6 status and grade 3b follicular lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 5 are phase 2 (5 open), 1 is phase 2/phase 3 (1 open), and 4 are phase 3 (4 open) [4].

BCL6 is altered in 11.11% of primary mediastinal B-cell lymphoma patients [3].

BCL6 is an inclusion criterion in 12 clinical trials for primary mediastinal B-cell lymphoma, of which 12 are open and 0 are closed. Of the trials that contain BCL6 status and primary mediastinal B-cell lymphoma as inclusion criteria, 6 are phase 1 (6 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) [4].

BCL6 is altered in 1.14% of mantle cell lymphoma patients [3].

BCL6 is an inclusion criterion in 12 clinical trials for mantle cell lymphoma, of which 9 are open and 3 are closed. Of the trials that contain BCL6 status and mantle cell lymphoma as inclusion criteria, 6 are phase 1 (4 open), 5 are phase 1/phase 2 (5 open), and 1 is phase 2 (0 open) [4].

BCL6 is altered in 5.28% of follicular lymphoma patients [3].

BCL6 is an inclusion criterion in 11 clinical trials for follicular lymphoma, of which 8 are open and 3 are closed. Of the trials that contain BCL6 status and follicular lymphoma as inclusion criteria, 6 are phase 1 (3 open), 4 are phase 1/phase 2 (4 open), and 1 is phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 10 clinical trials for Burkitt lymphoma, of which 7 are open and 3 are closed. Of the trials that contain BCL6 status and Burkitt lymphoma as inclusion criteria, 3 are phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (5 open) [4].

BCL6 is altered in 11.11% of mediastinal large B-cell lymphoma patients [3].

BCL6 is an inclusion criterion in 9 clinical trials for mediastinal large B-cell lymphoma, of which 7 are open and 2 are closed. Of the trials that contain BCL6 status and mediastinal large B-cell lymphoma as inclusion criteria, 3 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [4].

BCL6 is an inclusion criterion in 9 clinical trials for B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma, of which 7 are open and 2 are closed. Of the trials that contain BCL6 status and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (2 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [4].

BCL6 is an inclusion criterion in 9 clinical trials for primary cutaneous diffuse large B-cell lymphoma, leg type, of which 9 are open and 0 are closed. Of the trials that contain BCL6 status and primary cutaneous diffuse large B-cell lymphoma, leg type as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (2 open), 3 are phase 2 (3 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [4].

BCL6 is altered in 5.85% of B-cell non-hodgkin lymphoma patients [3].

BCL6 is an inclusion criterion in 8 clinical trials for B-cell non-hodgkin lymphoma, of which 7 are open and 1 is closed. Of the trials that contain BCL6 status and B-cell non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [4].

BCL6 is an inclusion criterion in 8 clinical trials for diffuse large B-cell lymphoma associated with chronic inflammation, of which 8 are open and 0 are closed. Of the trials that contain BCL6 status and diffuse large B-cell lymphoma associated with chronic inflammation as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [4].

BCL6 is an inclusion criterion in 7 clinical trials for ALK-positive large B-cell lymphoma, of which 7 are open and 0 are closed. Of the trials that contain BCL6 status and ALK-positive large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 2 (3 open), and 2 are phase 3 (2 open) [4].

BCL6 is an inclusion criterion in 7 clinical trials for germinal center B-cell-like diffuse large B-cell lymphoma, of which 7 are open and 0 are closed. Of the trials that contain BCL6 status and germinal center B-cell-like diffuse large B-cell lymphoma as inclusion criteria, 2 are phase 1 (2 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (1 open) [4].

BCL6 is an inclusion criterion in 7 clinical trials for HHV8-positive diffuse large B-cell lymphoma, not otherwise specified, of which 7 are open and 0 are closed. Of the trials that contain BCL6 status and HHV8-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 4 are phase 2 (4 open), 1 is phase 2/phase 3 (1 open), and 2 are phase 3 (2 open) [4].

BCL6 is an inclusion criterion in 6 clinical trials for marginal zone lymphoma, of which 5 are open and 1 is closed. Of the trials that contain BCL6 status and marginal zone lymphoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2/phase 3 (1 open) [4].

BCL6 is altered in 4.95% of non-hodgkin lymphoma patients [3].

BCL6 is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain BCL6 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [4].

BCL6 is an inclusion criterion in 5 clinical trials for diffuse large B-cell lymphoma activated B-cell type, of which 5 are open and 0 are closed. Of the trials that contain BCL6 status and diffuse large B-cell lymphoma activated B-cell type as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is no phase specified (1 open) [4].

BCL6 is an inclusion criterion in 5 clinical trials for intravascular large B-cell lymphoma, of which 5 are open and 0 are closed. Of the trials that contain BCL6 status and intravascular large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 2 (2 open), 1 is phase 2/phase 3 (1 open), and 1 is phase 3 (1 open) [4].

BCL6 is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 4 are open and 0 are closed. Of the trials that contain BCL6 status and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (3 open) [4].

BCL6 is an inclusion criterion in 4 clinical trials for Richter syndrome, of which 3 are open and 1 is closed. Of the trials that contain BCL6 status and Richter syndrome as inclusion criteria, 1 is phase 1 (1 open) and 3 are phase 1/phase 2 (2 open) [4].

BCL6 is altered in 1.82% of hodgkin lymphoma patients [3].

BCL6 is an inclusion criterion in 3 clinical trials for hodgkin lymphoma, of which 1 is open and 2 are closed. Of the trials that contain BCL6 status and hodgkin lymphoma as inclusion criteria, 3 are phase 1 (1 open) [4].

BCL6 is altered in 0.48% of multiple myeloma patients [3].

BCL6 is an inclusion criterion in 3 clinical trials for multiple myeloma, of which 2 are open and 1 is closed. Of the trials that contain BCL6 status and multiple myeloma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (0 open) [4].

BCL6 is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain BCL6 status and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

BCL6 is an inclusion criterion in 3 clinical trials for Burkitt leukemia, of which 3 are open and 0 are closed. Of the trials that contain BCL6 status and Burkitt leukemia as inclusion criteria, 3 are phase 2 (3 open) [4].

BCL6 is an inclusion criterion in 3 clinical trials for primary central nervous system lymphoma, of which 2 are open and 1 is closed. Of the trials that contain BCL6 status and primary central nervous system lymphoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 3 clinical trials for waldenstrom macroglobulinemia, of which 2 are open and 1 is closed. Of the trials that contain BCL6 status and waldenstrom macroglobulinemia as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

BCL6 is altered in 0.17% of chronic lymphocytic leukemia/small lymphocytic lymphoma patients [3].

BCL6 is an inclusion criterion in 2 clinical trials for chronic lymphocytic leukemia/small lymphocytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain BCL6 status and chronic lymphocytic leukemia/small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 2 clinical trials for angioimmunoblastic T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain BCL6 status and angioimmunoblastic T-cell lymphoma as inclusion criteria, 2 are phase 3 (2 open) [4].

BCL6 is an inclusion criterion in 2 clinical trials for follicular T-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain BCL6 status and follicular T-cell lymphoma as inclusion criteria, 2 are phase 3 (2 open) [4].

BCL6 is an inclusion criterion in 2 clinical trials for lymphomatoid granulomatosis, of which 2 are open and 0 are closed. Of the trials that contain BCL6 status and lymphomatoid granulomatosis as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 2 clinical trials for mature B-cell lymphoma/leukemia, of which 0 are open and 2 are closed. Of the trials that contain BCL6 status and mature B-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [4].

BCL6 is an inclusion criterion in 2 clinical trials for peripheral T-cell lymphoma, of which 1 is open and 1 is closed. Of the trials that contain BCL6 status and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 3 (1 open) [4].

BCL6 is altered in 3.85% of small cell lung carcinoma patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is altered in 3.98% of head and neck squamous cell carcinoma patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for head and neck squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is altered in 5.85% of mature B-cell non-hodgkin lymphoma patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for mature B-cell non-hodgkin lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and mature B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BCL6 is altered in 1.97% of ovarian carcinoma patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and ovarian carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is altered in 1.9% of indolent non-hodgkin lymphoma patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for indolent non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and indolent non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is altered in 2.0% of hematopoietic and lymphoid malignancy patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 2 (0 open) [4].

BCL6 is altered in 2.35% of mature T-cell and NK-cell non-hodgkin lymphoma patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

BCL6 is altered in 0.52% of acute myeloid leukemia patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for acute myeloid leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and acute myeloid leukemia as inclusion criteria, 1 is phase 2 (0 open) [4].

BCL6 is altered in 1.08% of breast carcinoma patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is altered in 0.56% of soft tissue sarcoma patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is altered in 0.8% of pancreatic carcinoma patients [3].

BCL6 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and pancreatic carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and anaplastic large cell lymphoma as inclusion criteria, 1 is phase 2 (0 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for anaplastic large cell lymphoma, ALK-positive, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and anaplastic large cell lymphoma, ALK-positive as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for atypical Burkitt/Burkitt-like lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and atypical Burkitt/Burkitt-like lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for B-cell acute lymphoblastic leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and B-cell acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for Burkitt-like lymphoma with 11q aberration, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and Burkitt-like lymphoma with 11q aberration as inclusion criteria, 1 is phase 1 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for composite lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and composite lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for EBV-positive mucocutaneous ulcer, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and EBV-positive mucocutaneous ulcer as inclusion criteria, 1 is phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue as inclusion criteria, 1 is phase 1 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for grade 1 follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and grade 1 follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for grade 2 follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and grade 2 follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for grade 3 follicular lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and grade 3 follicular lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for large B-cell lymphoma with IRF4 rearrangement, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and large B-cell lymphoma with IRF4 rearrangement as inclusion criteria, 1 is phase 1 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for lymphoplasmacytic lymphoma, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell lymphoma/leukemia, of which 0 are open and 1 is closed. Of the trial that contains BCL6 status and mature T-cell and NK-cell lymphoma/leukemia as inclusion criteria, 1 is phase 1 (0 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for nodal marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and nodal marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for nodal peripheral T-cell lymphoma with TFH phenotype, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and nodal peripheral T-cell lymphoma with TFH phenotype as inclusion criteria, 1 is phase 3 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and plasma cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for plasmablastic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and plasmablastic lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for primary effusion lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and primary effusion lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for small lymphocytic lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and small lymphocytic lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

BCL6 is an inclusion criterion in 1 clinical trial for splenic marginal zone lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BCL6 status and splenic marginal zone lymphoma as inclusion criteria, 1 is phase 1 (1 open) [4].